Literature DB >> 19126401

Substrate-specific reduction of PP2A activity exaggerates tau pathology.

Natasha Deters1, Lars M Ittner, Jürgen Götz.   

Abstract

Phosphorylation of the microtubule-associated protein tau is regulated by the balanced interplay of kinases and phosphatases. Disturbance of this balance causes hyperphosphorylation of tau and neurofibrillary tangle formation in Alzheimer's disease brain. Here, we crossed Dom5 mice that express a substrate-specific dominant negative mutant form, L309A Calpha, of protein phosphatase 2A (PP2A) with neurofibrillary-tangle-forming P301L mutant tau transgenic pR5 mice. This exacerbated the tau pathology of pR5 mice significantly. Double-transgenic Dom5/pR5 mice showed 7-fold increased numbers of hippocampal neurons that specifically phosphorylated the pathological S422 epitope of tau. They showed 8-fold increased numbers of tangles compared to pR5 mice, in agreement with our previous finding that tangle formation is correlated with and preceded by phosphorylation of tau at the S422 epitope. This suggests that, in addition to kinases, PP2A and its regulatory subunits may be a therapeutic target for Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126401     DOI: 10.1016/j.bbrc.2008.12.140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

1.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

Review 3.  Protein phosphatases and Alzheimer's disease.

Authors:  Steven P Braithwaite; Jeffry B Stock; Paul J Lombroso; Angus C Nairn
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 4.  The role of tau in Alzheimer's disease and related disorders.

Authors:  Rodrigo Medeiros; David Baglietto-Vargas; Frank M LaFerla
Journal:  CNS Neurosci Ther       Date:  2010-06-14       Impact factor: 5.243

5.  APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer's disease transgenics.

Authors:  M P Vitek; D J Christensen; D Wilcock; J Davis; W E Van Nostrand; F Q Li; C A Colton
Journal:  Neurodegener Dis       Date:  2012-02-09       Impact factor: 2.977

6.  Lewy-like aggregation of α-synuclein reduces protein phosphatase 2A activity in vitro and in vivo.

Authors:  J Wu; H Lou; T N M Alerte; E K Stachowski; J Chen; A B Singleton; R L Hamilton; R G Perez
Journal:  Neuroscience       Date:  2012-01-25       Impact factor: 3.590

Review 7.  Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Authors:  Ping Zheng; Sandy R Shultz; Chris M Hovens; Dennis Velakoulis; Nigel C Jones; Terence J O'Brien
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

10.  Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice.

Authors:  Kim M Gerecke; Yun Jiao; Viswajeeth Pagala; Richard J Smeyne
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.